Navigation Links
Treatment For Prostate Cancer Relapse Linked To Marital Status

A team of researchers at Fox Chase Cancer Center in Philadelphia report that single men who have a relapse of prostate cancer may not turn up to seek fresh treatment. //

The findings of the study were presented on the behalf of the Radiation Therapy Oncology Group by Dr. Andre Konski at the American Society for Therapeutic Radiation and Oncology annual meeting that is in progress in Denver. Researchers at the Fox Chase Cancer Center analyzed the data of various men who returned for radiation therapy for metastatic prostate cancer. They looked for the outcomes keeping in mind the marital status of the men. Konski said that single men were unlikely to return for retreatment.

"We need to come up with strategies to support them, such as nurse follow-up and patient navigators who can help them through the healthcare system," he added. He also observed that the trend might have something to do with the fact that single men have markedly less social support and encouragement to seek treatment. "We are just starting to scratch the surface of this population as far as what they need or their attitudes," Konski said adding that these findings presented a case for instituting an aggressive therapy the first time around in men whose prostate cancer was likely to relapse.
'"/>




Page: 1

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
(Date:10/7/2008)...alth-related Questions for Tonight,s,Presidential ...- WebMD, the leading source of,health information,...ial,candidates, proposed health care policies, loc...t the candidates, stance on health insurance, medi... public health issues., The in-depth coverage is ...
(Date:10/7/2008)...PRNewswire-USNewswire/ -- The Ohio Nurses,Associat...ced today its,final round of endorsed candidates f...o Senate:, SD 26 Karen Gillmor (R) Tiffin, Ohio ...(R) Grove City;, HD 28 Connie Pillich (D) Cincinn...These ONA-endorsed candidates for the Ohio General...
(Date:10/7/2008)...wswire-USNewswire/ -- Kristi Yamaguchi, Olympic,Go... the Stars, has been,named chairperson for the 200...gn in an effort to help raise funds in support of ...e and promote lung health., The American Lung Ass...o conquer Tuberculosis. Today, the Lung Associatio...
(Date:10/7/2008)...ar to more expensive whole-leg color ultrasound, ...lthDay News) -- An older, simpler test to look for...osis, or DVT -- is as effective as a newer, more e...searchers found that 2-point ultrasonography of th...trasound -- was as good at detecting DVT as the ne...
Breaking Medicine News(10 mins):Health News:WebMD Highlights Presidential Candidates' Views on Health Care 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 3Health News:Kristi Yamaguchi Chairs American Lung Association Christmas Seals Campaign 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3
...rom a serious kidney ailment died Saturday after j...here//, apparently because he could not afford the...dow of the nephrology ward of the Sanjay Gandhi Po...ces, where he was being treated, hospital sources ...
...ug has been for the first time given the green sig... emotional disturbances// in children and teenager...ug Administration. An antipsychotic drug generally...Risperidone will thus become the first one in its ...
...on form of adult leukemia will require blocking mu... researchers at The University of Texas M. D. Ande... the journal Blood. The research team examined blo...ts with acute myelogenous leukemia (AML) and then ...
...or logical applications apparently also works very...ogy Professor Randall O'Reilly of the University//...much light in the recesses of research trying to f...elligently. While reviewing computer models of th...
Other Medicine News:Health News:Three Molecular Triggers Threaten Leukemia Patients 2Health News:Three Molecular Triggers Threaten Leukemia Patients 3
(Date:10/7/2008)...ented Immunologic Changes Induced by ...nal Data Indicates Potential in Treating Inflammat...ire/ -- Alba Therapeutics Corporation,presented re...merican,College of Gastroenterology (ACG) 2008 Ann...004, the first Phase IIa trial conducted in celiac...
(Date:10/7/2008)... Annual Scientific Meeting -, ORLANDO, Fla., Oct....als, Inc. (formerly Microbia, Inc.) and Forest Lab...presentation of results from a Phase,2b study asse...ients with,irritable bowel syndrome with constipat...nce- daily oral dosing of linaclotide, across a ra...
(Date:10/7/2008)...acebo-Controlled Phase II Study Shows Sta... MOUNTAIN VIEW, California, October 7 /PRNewswire...ature Phase II data from the,therapeutic prostate ...n,obtained as part of the recently entered partner...he US., The results from the Phase II prospective...
(Date:10/7/2008)...Newswire-FirstCall/ --, - 125 Patient, Prospectiv...ws Statistically Significant Improved Overall Surv...e phase II data from the,therapeutic prostate canc...tained as part of the recently entered partnership...S., The results from the Phase II prospective ran...
Breaking Medicine Technology:Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 5Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 1Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 2Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 3Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 4Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 5Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 6Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 7Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 8Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 9Meningitis Shot Available Effective Year Round 4629 1Meningitis Shot Available Effective Year Round 4629 2Meningitis Shot Available Effective Year Round 4629 3Staying sharp in San Diego 4626 1Gentiva 28R 29 Health Services to Present November 7 at CIBC Healthcare Conference in New York 4623 1Gentiva 28R 29 Health Services to Present November 7 at CIBC Healthcare Conference in New York 4623 2Gentiva 28R 29 Health Services to Present November 7 at CIBC Healthcare Conference in New York 4623 3
...7 /PRNewswire-FirstCall/ --,Pharmacyclics, Inc. an... novel histone deacetylase (HDAC) inhibitor and,Br...esentations,will take place at the American Associ...ng being held April 14-18, 2007, at the Los,Angele...e presentations are as follows:, Sunday, Apri...
...t EASL Conference in Barcelona,Spain, VANCOUVER a...Call/ - MIGENIX Inc. , a clinical-stage developer,... top-line results,confirming the previously announ... evidence of clinical benefit, safety and,tolerabi...osidase,inhibitor, celgosivir (MX-3253), in combin...
Other Medicine Technology:Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 2Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 3Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 2New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 3New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 5New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 6New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 7New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 8
Cordis DUCOR Catheters are available in a broad variety of French sizes and configurations. These catheters combine an atraumatic tip with either a braided or non-braided body.
The advanced center-of-the-arc system allows an infinite choice of trajectories. The system's lightweight durable frame provides accuracy, simplicity, patient mobility and accessibility.
The CRW system epitomizes simplicity, quality assurance, and versatility.
Used for complex diagnostic and interventional procedures.
Medicine Products: